Latest Breaking News On - Callaghan innovation technology incubator programme - Page 1 : comparemela.com

BioOra, the Kiwi biotech leading the fight in immune cell cancer therapy

BioOra, the Kiwi biotech leading the fight in immune cell cancer therapy
voxy.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from voxy.co.nz Daily Mail and Mail on Sunday newspapers.

New zealandNew zealandersMalaghan instituteCallaghan innovation technology incubator programmeMedical researchBridgewest venturesCallaghan innovationTechnology incubator

Dr Andi Grant is appointed to CEO at BioOra

/PRNewswire/ BioOra Limited, a Bridgewest Group portfolio company, appoints new CEO, Dr. Andi Grant. Dr. Grant has an accomplished career in global.

United statesNew zealand generalNew zealandUnited kingdomMike zablockiPeter crabtreeJenny bourbielResearch is new zealandBridgewest groupMalaghan institute of medical researchCallaghan technology incubatorCallaghan innovation technology incubator programmeBridgewest capital managementUniversity of cambridgeTechnology incubatorMalaghan institute

Dr Andi Grant is appointed to CEO at BioOra

Dr Andi Grant is appointed to CEO at BioOra
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew zealand generalNew zealandUnited kingdomMike zablockiPeter crabtreeJenny bourbielResearch is new zealandBridgewest groupMalaghan institute of medical researchCallaghan technology incubatorCallaghan innovation technology incubator programmeBridgewest capital managementUniversity of cambridgeTechnology incubatorMalaghan institute

University of Auckland: Uni biotech spin-off developing cancer treatment gets $15m boost

TamoRx, a biotech start-up spun out of the University of Auckland, is getting $15.25m to accelerate the development of a treatment for cancer.Founded by Dr Joanna Mathy and Professor Rod Dunbar from the School of Biological Sciences, the company aims

New zealandJoanna mathySchool of biological sciencesResearch commercialisation fundUniversity of auckland inventor fundCallaghan innovation technology incubator programmeUniversity of aucklandProfessor rod dunbarBiological sciencesBrandon capitalAuckland inventor fundCallaghan innovationCallaghan innovation technology incubatorMedical research commercialisation fund

$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments

Date Time $14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments Amaroq Therapeutics, a new biotech start-up spun out of the University of Otago, with one of the world’s most advanced programs in next-generation RNA therapy to target cancer has secured NZ$14m investment to accelerate development. Dr Sarah Diermeier. The study of long non-coding RNAs (lncRNAs), often referred to as “dark matter” of the genome, are molecules naturally present in cells. Acting as key cell regulators despite not coding for proteins they have become one of the hottest areas of research globally. The emergence of new sequencing technologies has provided the opportunity to research these molecules further with significant investments being made globally into companies focusing on this area.

New yorkUnited statesNew zealandDavid christensenSarah diermeierDavid spectorDuncan mackintoshUniversity of otagoResearch commercialisation fundCold spring harbor laboratory new yorkCallaghan innovation technology incubator programmeOtago innovation ltdAmaroq therapeuticsChief scientific officerBrandon capitalCure kids